Therapeutics Company Presents New Hope For Neuropathy Patients

Sonnet BioTherapeutics (NASDAQ: SONN), a biopharmaceutical company that specializes in developing innovative targeted biologic drugs, recently announced preliminary safety data from the ongoing Phase 1b/2a clinical trial of SON-080. This drug, which is being developed for the treatment of CIPN, met the study's initial pre-specified objective. This development could have significant implications for patients suffering from CIPN and for the future of Sonnet BioTherapeutics. $Sonnet BioTherapeutic(SONN.US)$